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InﬂammationThis report reviews structurally related phospholipid oxidation products that are biologically active where
molecular mechanisms have been deﬁned. Phospholipids containing polyunsaturated fatty acyl residues
are chemically or enzymatically oxidized to phospholipid hydroperoxides, which may fragment on either
side of the newly introduced peroxy function to form phospholipids with a truncated sn-2 residue. These
truncated phospholipids not subject to biologic control of their production and, depending on the sn-2 resi-
due length and structure, can stimulate the plasma membrane receptor for PAF. Alternatively, these chemi-
cally formed products can be internalized by a transport system to either stimulate the lipid activated
nuclear transcription factor PPARγ or at higher levels interact with mitochondria to initiate the intrinsic ap-
optotic cascade. Intracellular PAF acetylhydrolases speciﬁcally hydrolyze truncated phospholipids, and not
undamaged, biosynthetic phospholipids, to protect cells from oxidative death. Truncated phospholipids are
also formed within cells where they couple cytokine stimulation to mitochondrial damage and apoptosis. The
relevance of intracellular truncated phospholipids is shown by the complete protection from cytokine induced
apoptosis by PAF acetylhydrolase expression. This protection shows truncated phospholipids are the actual ef-
fectors of cytokine mediated toxicity. This article is part of a Special Issue entitled: Oxidized phospholipids—
their properties and interactions with proteins.
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l rights reserved.1. Introduction
This review describes the effects and metabolism of several oxida-
tively generated phospholipids where both structures and a molecu-
lar mechanism of action have been identiﬁed. The number of
phospholipid structures formed after oxidation of their esteriﬁed
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that the examination, formation, structures, functions of biologically
active oxidized phospholipids and their products has grown so ro-
bustly since we ﬁrst reported the formation of Platelet-activating
Factor (PAF)-like phospholipids formed by phospholipid oxidation
in the absence of enzymatic synthesis [2]. The number of structures
and the types of activities oxidatively modiﬁed phospholipids display
are now elegantly summarized in recent reviews of the area by di-
verse and informed investigators [1,3–6]. There also is an excellent
summary of the diversity of actions and events induced by products
of oxidatively modiﬁed phospholipids, including the upregulation
of cellular signaling pathways, induction of varied types of stresses,
formation of neoepitopes, and alteration of immune responses [4].
Oxidized phospholipids are the ligands in oxidized lipoproteins recog-
nized by the scavenger receptor CD36 [7], they mark systemic alcoholic
stress [8], and oxidized phosphatidylserine marks apoptotic cells for
phagocytosis [9]. Intracellular oxidized phospholipids even speciﬁcally
adduct key kringle proteins before secretion [10], revealing their pres-
ence in normal cellular metabolism. The structures and the diverse
pathologic events they promote are now well summarized in a recent
compendium describing the formation and actions of oxidized phos-
pholipids [4].
The types and routes of formation of oxidized phospholipids are
now understood in detail, but a detailed and precise understanding
of how this myriad of modiﬁed phospholipids modulate cellular and
organ systems is not nearly as clear. The effects of oxidized phospho-
lipids on intracellular second messenger systems include increased
intracellular Ca+2 or cAMP, but how these and other intracellular
mediators respond to oxidized phospholipids is less well understood.
The goal here is to summarize three mechanisms where the structure,
receptors and mechanism of action are all deﬁned to elucidate path-
ways connecting oxidized phospholipids to speciﬁc events. Inciting
stimuli and eventual (patho)physiologic outcomes vary, but at least
several pathways now have been elucidated at molecular level. This
review therefore focuses on the Platelet-activating Factor inﬂammatory
response, PPARγ signaling, and mitochondria-dependent programmed
cell death as three disparate examples of the way by which oxidized
phospholipids generate biologic responses. These mechanisms are
diverse, and hint that other roles and mechanisms of action of oxidized
phospholipids will be equally diverse.
One class of oxidatively generated phospholipids structurally, and
hence functionally, mimics the powerful and pleiotropic inﬂammatory
mediator, Platelet-activating Factor (PAF). PAF, and its oxidatively
formed, and unregulated, PAF-like phospholipids mimetics, act on the
single G protein coupled PAF receptor present on the surface of all
cells of the innate immune system. The PAF receptor is additionally
expressed on nearly all cells of the cardiovascular system. A second
class of phospholipid truncation products activates the lipid-activated
transcription factor PPARγ. Finally, oxidatively truncated phospholipids
interact with the pro-apoptotic protein Bid to depolarize and damage
mitochondria that allows cytochrome c and apoptosis-inducing factor
escape to initiate the intrinsic pathway to apoptotic cell death. Since
choline phospholipids are internalized in part through a TMEM30a
transport system [11], extracellular oxidized phospholipids have access
to intracellular targets.
Phospholipids with choline sn-3 headgroups have been examined
as targets of oxidation for several reasons, historic as well as practical,
but to the extent that the oxidation or remodeling of esteriﬁed fatty
acyl residues provoke new biology, the nature of the head group
may be inconsequential. Choline phospholipids are the abundant
class of membrane and especially lipoprotein phospholipid pools,
and so their oxidation is likely. Historically, the ﬁrst phospholipid ox-
idation products with a deﬁned mechanism of activation were those
that activated the G protein coupled receptor for Platelet-activating
Factor (PAF) [2], and the PAF receptor displays marked speciﬁcity
for the sn-3 choline headgroup [12]. And, a practical consideration isthat choline is a quaternary amine and is not derivatized by reactive
aldehydes generated by reactive aldehydes generated by Hock frag-
mentation of esteriﬁed fatty acyl hydroperoxides. Other phospho-
lipids are oxidized in parallel with choline phospholipids, forming
homologous products. Phosphatidylserine oxidation, in particular,
has a distinct and key role in mitochondrial dysfunction, apoptosis,
and recognition of apoptotic cells [9]. Ethanolamine phospholipids
are oxidized during platelet activation and are sites of prostanoid
formation [13,14]. To a great extent, then, the nature of the sn-3 head-
group (except in the case of PAF signaling) is likely to be immaterial,
although this has yet to be explicitly determined.
Phospholipid truncation products not only interact with inﬂamma-
tory receptors and lipid transfer factors – the pro-apoptotic protein
Bid is in fact a phospholipid binding and transfer protein [15] – but
are more soluble in the aqueous phase than their parental phospho-
lipids sequestered in phospholipid bilayers and the monolayer of lipo-
protein particles. This property alters metabolism of truncated
phospholipids relative to bulk phospholipid, and alters their enzymatic
metabolism, transcellular transport, and clearance from the circulatory
system. Oxidatively truncated phospholipids increase in the circulation
during atherosclerosis [16] and alcoholic steatohepatitis [17], and these
external phospholipids are actively internalized by a choline phospho-
lipid transport system [11]. Circulating oxidatively truncated phospho-
lipids, and not those intercalated in lipoprotein particles, are cleared
with great rapidity, with a t1/2 b30 s, primarily by entry into liver and
kidney (below). This rapid accumulation of circulating truncated phos-
pholipid means they enter the circulation at least as rapidly as they are
cleared, elucidating an unappreciated extensive ﬂux of truncated phos-
pholipids through the circulation during oxidative and inﬂammatory
stresses. This also emphasizes the point that exogenous truncated phos-
pholipids have access to the intracellular environment and can modu-
late intracellular processes (Fig. 1).
Oxidatively truncated phospholipids, but not their biosynthetic
phospholipid precursors, are substrates for a class of phospholipases
A2, the group VII class of PAF acetylhydrolases. These enzymes selec-
tively recognize the sn-2 acetyl residue of PAF, but also speciﬁcally
hydrolyze the fatty acyl fragment that remains esteriﬁed in the sn-2
position of the phospholipid glycerol backbone after fragmentation
of the oxidized fatty acyl residue [19]. These phospholipases, then, ac-
tually are highly speciﬁc oxidized phospholipid phospholipases. Con-
servation of these enzymes and function over 100 Ma of evolution
[18] show the continuing importance of speciﬁcally removing phos-
pholipid oxidation products to aerobic organisms.
Oxidatively truncated phospholipids are also generated within
cells responding to pro-apoptotic cytokines such as TNFα, and these
mobile phospholipid oxidation products in fact are required mediators
of TNFα-induced cytotoxicity. The required participation of these lipids
is revealed by speciﬁcally depleting oxidatively truncated phospho-
lipids through PAF acetylhydrolase expression, which abolishes cell
death [18] (Latchoumycandane et al., J Biol Chem, 2012 in press). Cyto-
kine stimulated cells therefore generate sufﬁcient oxidizing radicals to
overwhelm normal cellular defenses to form truncated phospholipids
that are the actual mediators of mitochondrial dependent cell death.
The way phospholipid truncation products form, the way oxida-
tively truncated phospholipids display new biologic activities, and
the new way they are metabolized and transported are considered
in more detail as follows.2. Oxidized and oxidatively modiﬁed phospholipids
There is a tremendous diversity in sn-1 and sn-2 fatty acyl residues
esteriﬁed in cellular phospholipids, and this diversity is multiplied by
the several phosphoester headgroups esteriﬁed at the 3-position of
the glycerolipid. Oxidation to new phospholipid species exponentially
expands this diversity. Diversity is further broadened by the nature of
Fig. 1. Exogenous and cytokine-induced truncated phospholipids stimulate deﬁned biologic processes. External truncated choline phospholipids are transported by lipoproteins and
albumin, while retaining appreciable aqueous solubility. Truncated choline phospholipids with short sn-2 residues activate the G protein coupled PAF receptor that stimulates
endogenous second messenger formation. Exogenous truncated phospholipids are internalized through a TMEM30a translocation system, allowing external truncated phospholipids
access to the cytoplasm. Truncated phospholipids are also generated within cells by cytokine signaling that activates NADPH oxidase. Internal truncated phospholipid associate with
Bid, depolarizingmitochondria and promoting intrinsic apoptotic cellular death. Intracellular PAF acetylhydrolase speciﬁcally hydrolyzes oxidatively damaged phospholipids, and protects
cells from cytokine and oxidative death.
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hence phospholipid oxidation.
The majority of glycerophospholipids remain as they are synthe-
sized, and so contain fatty acyl residues esteriﬁed at both the sn-1
and sn-2 position of a glycerol molecule that forms the backbone of
phospholipids. These are diacyl phospholipids and are deﬁned as
phosphatidylcholines, or ethanolamines, serines, etc., depending on
the sn-3 headgroup. Since these are the most commonly discussed
phospholipids “phosphatidylcholine” would seem to cover all the
lipids with choline headgroups, but it does not. There are two other
classes of choline glycerophospholipids – the term that does cover
all phospholipids with this headgroup – that are relevant to phospho-
lipid oxidation, and biologic activity.
The ﬁrst class of non-phosphatidylcholines are those that contain
an ether (C\O\C) bond at the sn-1 position rather than an acyl
bond from the carboxylate of esteriﬁed fatty acyl residues. These are
ether phospholipids formed from the condensation of a fatty alde-
hyde, rather than a fatty acid, at the sn-1 position. Ether phospho-
lipids are relevant as they can support a range of functions not
available to diacyl lipids [20]. These choline phospholipids are abun-
dant in circulating white blood cells, accounting for up to half of the
choline phospholipid pool of these inﬂammatory cells [21]. These
ether choline phospholipids are essential in inﬂammation because
these are the precursors for the potent inﬂammatory mediator
Platelet-activating Factor (more on this below) and for arachidonate
that will be metabolized to thromboxane, prostaglandins and leuko-
trienes. Diacyl phosphatidylcholine analogs of PAF are, depending
on the assay, up to 1000-fold less potent than their ether phospholip-
id counterparts as PAF receptor agonists. This is relevant because
non-selective oxidation of inﬂammatory cell membranes attacksether phospholipid structures as well as diacyl phospholipids, and
the truncation products of ether phospholipids potently induce PAF-
like biologic responses by cells displaying the PAF receptor because
the sensitivity of the receptor for PAF and its mimetics is so profound.
The second class of non-phosphatidylcholine choline phospho-
lipids is also an ether phospholipid, but these additionally contain a
double bond at the C1 position of the fatty ether residue. These are
plasmalogens, and are distinguished by the lability of their ether
bond. Plasmalogens, both choline and ethanolamine, are readily oxi-
dized, and have been proposed as membrane-associated oxygen
traps [22].
3. Oxidative phospholipid truncation
Oxidized phospholipids are glycerophospholipids with one or
more newly introduced oxy functions (Fig. 2). These include peroxy
(OO•), hydroperoxy (OOH)or hydroxy (OH) functions formed by radical
or enzymatic attack on a polyunsaturated fatty acyl residue esteriﬁed
in the glycerol backbone of the phospholipids. Since polyunsaturated
fatty acyl residues are preferentially esteriﬁed in the sn-2 position of
the three-carbon glycerol backbone, oxidized phospholipids preferen-
tially sport oxidized acyl residues in this central position.
Oxidatively truncated phospholipids are chemical reaction products
of phospholipid (hydro)peroxides. Oxidized phospholipids, like oxi-
dized free fatty acids [23,24], are subject to secondary radical attack,
rearrangement of the fatty acyl chain and introduction of other, often
oxy, functions. Free radical reactions are not constrained by the Pauli
exclusion principle and each fatty residue is the precursor of a host of
reaction products. This complexity, as noted, is further complicated by
the great diversity of esteriﬁed fatty acyl residues. The result is that
Fig. 2. Oxidative phospholipid truncation. A. Phospholipids with varying sn-1 bonds (ether or acyl) of varied sn-3 head groups (X) undergo identical oxidation of the sn-2 polyun-
saturated fatty acyl residue. The abundant docosahexaenoyl ω-3 fatty acyl residue has a proximal oleﬁnic bond between carbon atoms 4 and 5. Chemical peroxidation by reactive
free radicals (ROS) preferentially reﬂects attack at the C4 atom, and shifts the double bond. The peroxyl radical (OO•) abstracts a hydrogen atom to form a hydroperoxide (OOH).
Peroxy radicals fragment on either side of the newly introduced oxygen atom to produce methyl terminated truncated fatty acids that are one carbon atom shorter than those that
fragment just distal to the peroxy radical. This longer fragment retains the molecular oxygen at theω-end of the fragment. B. Platelet-activating Factor (PAF). PAF is phospholipid, 1-
O-alkyl-2-acetyl-sn-3-glycero-3-phosphocholine recognized at subnanomolar concentrations by a single G protein coupled receptor, the PAF receptor. This receptor recognizes the
sn-1 ether bond, the sn-3 choline headgroup, and especially the short sn-2 acetyl residue.
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products [1,19].
Oxidation of polyunsaturated fatty acids preferentially results in
isomers with the newly introduced oxygen at the outer oleﬁnic bond
of a series of double bonds in model systems, with reductants stabiliz-
ing and enhancing internal hydroperoxide isomers [24]. The mix of
inner and outer hydroperoxide isomers is therefore dynamically re-
sponsive to the environment where they form during oxidative attack,
with 12- and 15-lipoxygenases contributing to speciﬁc peroxide iso-
mers [25]. Phospholipid (hydro)peroxides fragment adjacent to the
newly introduce oxygen [24], tending to produce fragmentation prod-
ucts clustered around the position of the original position of the ﬁrst
and last oleﬁnic bond of esteriﬁed polyunsaturated fatty acids. The
proximal moiety of the fatty acyl residue remains esteriﬁed in the phos-
pholipid, with the distal portion of the newly fragmented fatty acyl res-
idue freed to enter the aqueous phase. This oxidative attack, then, forms
phospholipids with signiﬁcantly shortened sn-2 residues.
Esteriﬁed arachidonoyl (C20:4) residues with the proximal oleﬁnic
bond located between the 5th and 6th carbon atoms fragment to 4
and 5 carbon long fatty acyl remnants (reﬂecting fragmentation on
either side of the C5 peroxy function) that remain esteriﬁed in the
2-position of the parent phospholipid. Similarly, oxidation of esteri-
ﬁed docosahexaenoyl (C22:6) residues with their proximal 4,5 oleﬁnic
bonds favors products with 3 and 4 carbon long sn-2 residues. Be-
cause fragmentation of the fatty acyl chain occurs on either side of
the peroxyl site, the longer fragments (5 and 4 carbons long from
C20:4 or C22:6, respectively) include the newly introduced oxygen
atoms. This forms a newly made ω-oxy (C_O, COH, or COOH) func-
tion at the new end of the shortened chain. The one carbon shorter
fragments derived from the same phospholipid hydroperoxide pre-
cursor by fragmentation proximal to the peroxy function do not con-
tain the new oxygen atom, so these shorter fragments are terminated
with a methyl group. These are the shortest common fragmentation
products, but identical processes fragment peroxides located farther
down the chain to related, longer fragmented phospholipids. Reten-
tion of double bonds and rearrangement can produce highly reactiveα,β unsaturated carbonyls that are ligands for the scavenger receptor
CD36 or that chemically adduct proteins. Secondary oxidative attack
can shorten already oxidized sn-2 residues [26,27], and phospholipids
bearing the two-carbon acetyl residue are products of oxidative attack
on full length, membrane integrated polyunsaturated phospholipids.
Fragmentation to short truncated phospholipids has several con-
sequences, ranging from membrane disruption to conferring a new
ability to productively interact with receptors and their signaling pro-
grams. Oxidative attack on esteriﬁed arachidonoyl and docosahexaenoyl
residues produces phospholipids with PAF-like activity. Conversely,
attack of the more common linoleoyl and linolenoyl residues, with
the proximal oleﬁnic bond between carbons 9 and 10, produces 8 and
9 carbon long truncated phospholipids with less PAF-like activity, but
with more activity as PPARγ agonists and Bid-dependent agents of
apoptosis.
4. Oxidized phospholipids with deﬁned cellular targets
4.1. PAF-like activity
PAF-like phospholipids (Fig. 2A) are phospholipid oxidation products
bearing short sn-2 fatty acyl fragments that stimulate the receptor
for Platelet-activating Factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine). PAF (Fig. 2B) is a choline phospholipid, but a unique
one. It contains an sn-1 ether bond, and additionally is marked by its
novel sn-2 acetyl residue. The ether choline phospholipid precursors
of PAF are common in inﬂammatory cells [28] that make PAF. PAF
synthesis is regulated and only after stimulation is the sn-2 fatty
acyl residue hydrolyzed and replaced by an acetyl residue from
acetyl-Coenzyme A. PAF, then, is produced by stimulated cells and
only upon activation [12].
PAF is not only a potent agonist for platelets, but also for most
other cells of the inﬂammatory system (e.g. polymorphonuclear leu-
kocytes, macrophages endothelial cells, etc.), because it is the agonist
for the PAF receptor expressed by these cells. The PAF receptor is a single
G protein coupled receptor that recognizes the sn-1 ether bond, the
Fig. 3. Intermediate length truncated phospholipids. Oxidation of abundant sn-2 linoleoyl
(C18:2) shown here or linolenoyl (C18:3) generates truncated phospholipids with inter-
mediate length residues, some ofwhich are anions. Anionic residues are solvated by ﬂip-
ping the truncated residue from the apolar environment of a bilayer into the aqueous
phase [66]. This newly introduced charge enhances solubility, but is disruptive to lipid
packing.
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range of inﬂammatory and non-inﬂammatory activities [29] through
activation of endothelial cells that attract circulating inﬂammatory
cells to localize and initiate the inﬂammatory response [30].
PAF is the single known physiologic agonist of the PAF receptor,
but phospholipid truncation generates non-physiologic PAF receptor
agonists with the same actions as PAF since they functionally engage
the PAF receptor [2,31]. These phospholipids are structurally distinct
from PAF because they do not (generally) contain the sn-2 acetyl resi-
due of PAF, but rather a series of short, sn-2 fatty acyl fragments. They
may not even contain the ether bond of PAF, but because PAF is so
very potent, even PAF analogs can activate cells at subnanomolar con-
centrations [32]. Short, truncated phospholipids are inﬂammatory,
and especially so when they arise from platelets, monocytes and neu-
trophils that possess a signiﬁcant pool of ether choline phospholipids.
This means the critical roles of PAF in initiating and extending the in-
ﬂammatory response can be initiated instead by analogs generated
by unregulated chemical attack on common cellular and lipoprotein
phospholipids. The pathophysiologic presence of PAF is tightly con-
trolled by inﬂammatory signaling, whereas phospholipid oxidation is
temporally, spatially and uncontrollably initiated through unregulated
chemical events. The pro-inﬂammatory processes of atherosclerosis
and other oxidative stress reﬂect the inappropriate appropriation of
what should be a carefully controlled system.
Oxidized phospholipids circulate in association with lipoprotein
particles [33] during atherosclerosis and are components of the lipid
plaque of atherosclerotic lesions [16]. They circulate during the oxida-
tive and inﬂammatory stress induced by chronic ethanol ingestion
[17], and circulating oxidized phospholipids are valid markers of the
risk, extent and lesion burden of atherosclerosis [34]. Shortened and
fragmented phospholipid products activate platelets, monocytes and
polymorphonuclear lymphocytes through their PAF receptors [31,35],
linking these oxidatively modiﬁed lipids to inﬂammatory responses.
4.2. PPARγ agonists
Phospholipids with intermediate length sn-2 residues stimulate
the transcription factor Peroxisomal Proliferator Activated Receptor
gamma (PPARγ). PPARγ is a nuclear lipid-activated transcription fac-
tor, and select oxidatively truncated phospholipids [36] are ligands
and agonists of PPARγ [37]. Extracellular oxidatively truncated phos-
pholipids, after internalization, stimulate PPARγ, which in turn induces
cyclooxygenase-2 expression [38]. Cyclooxygenases initiate formation
of all prostaglandins and thromboxane A2, and are a key regulatory
point for their production.
The primary transcription factor controlling CD36 expression is
PPARγ. This scavenger receptor recognizes and binds oxidized low-
density lipoprotein [39] and apoptotic cells [40] through the oxidatively
modiﬁed phospholipids embedded in the particle or cell. PPARγ is itself
regulated by oxidatively truncated phospholipids [36] and CD36 is an
essential element in monocyte function. PPARγ has a critical role in
reverse cholesterolmetabolism [41], so phospholipid oxidation stimu-
lates turnover of the particles that contain it [42,43].
Lysophosphatidic acid, a phospholipid lacking an sn-2 residue, is
an essential intermediate in phospholipid metabolism and remodel-
ing, that also stimulates PPARγ [44]. Hydrolysis of truncated phos-
pholipids by phospholipases A2 produces lysophosphatidylcholines
that are substrates of phospholipases D (autotaxin) of activated plate-
lets [45]. Lysophosphatidic acid is an agonist for PPARγwhen present
as an extracellular circulating agonist [46] and when present as a
component of cellular lipid metabolism [47].
4.3. Exogenous pro-apoptotic oxidized phospholipids
Oxidatively truncated phospholipids with intermediate length sn-2
fragments (Fig. 3) directly interact with mitochondria. This damagesthe organelle's physical and functional integrity, permitting cytochrome
c escape. Cytoplasmic cytochrome c is problematic because it initiates
the intrinsic apoptotic cascade [48]. A common truncated phospholipid
of this class contains a 9-carbon long fatty acyl fragment terminated
with either an ω-terminal aldehyde or (after oxidation) a carboxylate.
The fragment thus is either 9-oxo-nonoanoyl or an azelaoyl (the trivial
name for a nine-carbon dicarboxylate fatty acid) residue that
remains esteriﬁed in the original lysophospholipid. These products are
abundant because they are derived from the most abundant esteriﬁed
polyunsaturated fatty acyl residue, esteriﬁed linoleic acid, and they
are the common product of a single oxidative reaction. Azelaoyl-
phosphatidylcholine is both expected as a direct oxidation product of
linoleoyl choline phospholipids, and can be unambiguously identiﬁed
by an intramolecular rearrangement in the gas phase during mass spec-
trometry that produces an azelaoyl mono methyl ester [36]. Azelaoyl
phosphatidylcholine is an obvious peak in the chromatogramof oxidized
lipoprotein particles [36], and accumulates in the circulation of both rats
and humans during chronic ethanol ingestion leading to alcoholic
steatohepatitis [17].
Exogenous azelaoyl choline phospholipid is apoptotic because it is
rapidly internalized, in part by a transport system described below,
where it rapidly becomes associated with mitochondria [48]. Associ-
ation of the truncated phospholipid with mitochondria depolarizes
the organelle, allowing it to swell. This allows apoptosis-inducing fac-
tor to escape to the cytoplasm and then to the nucleus to aid DNA
degradation. Mitochondrial swelling also allows cytochrome c to es-
cape to the cytoplasm. This is deleterious because it completes the
apoptosome that processes pro-caspase 9 to active caspase 9. Caspase
9 then activates pro-caspase 3, an effector protease of apoptosis, to its
active form. This pathway is activated by internalization of exogenous
oxidatively truncated phospholipids because irreversible inhibition of
caspase 9 blocks downstream caspase 3 activation and prevents apo-
ptosis induced by truncated phospholipids.
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duced by this class of truncated phospholipids because over-expression
of the anti-apoptotic protein Bcl-XL, which alters the ratio of pro-and
anti-apoptotic mitochondria interacting factors, blocks cytochrome c
escape and apoptosis [49]. Azelaoyl phosphatidylcholine is not alone
in this and its sn-1 ether species is twice as effective as this diacyl phos-
pholipids. Additionally, phospholipids with other remnants of frag-
mented phospholipids esteriﬁed at the sn-2 carbon also damaged
mitochondrial function and integrity.
The way that truncated phospholipids damage mitochondrial
structure and function is not fully known, but the interaction between
mitochondria and the relatively hydrophilic truncated phospholipid
is direct. It also is continuous because depolarization of isolated mito-
chondria by the truncated phospholipid is readily reversed by the ad-
dition of albumin that sequestered this lipid [49]. Recovery from
truncated phospholipid exposure by albumin shows that the amphi-
pathic phospholipid does not interfere with mitochondrial integrity
by dissolving their membranes. Rather, phospholipid intercalation into
mitochondria promotes swelling through the mitochondrial perme-
ability transition pore because blockade of the pore with cyclosporin
A interferes with the phospholipid-induced loss of the organelle's elec-
trochemical gradient. Furthermore, mitochondria isolated from Bcl-XL
over-expressing cells were protected from truncated phospholipid
depolarization, while organelles isolated from Bid−/− animals lacking
this pro-apoptotic Bcl-2 family member were resistant to this depolari-
zation. Recombinant full-length Bid restored sensitivity ofmitochondria
to azelaoyl-phosphatidylcholine. This then means that phospholipid
oxidation products physically interact withmitochondria to continually
depolarize this organelle. This occurs without permanent harm to the
organelle for short periods, although eventually loss of intra-organelle
components compromises mitochondrial function.
Bid, although amember of the Bcl-2 family of pro- and anti-apoptotic
proteins, uniquely possesses phospholipid binding and transfer activity
[50] that inserts lysophospholipids into mitochondrial membranes
[15]. Lysophospholipid binding alters the tertiary structure of the Bid
protein, and proteolytically truncated Bid is more effective in phospho-
lipid binding and stimulated release of cytochrome c from target mito-
chondria than intact Bid [51]. This connects truncated phospholipids,
caspase action and Bid as members of a common pathway. We ﬁnd
that Bid also mobilizes water-soluble oxidatively truncated phospho-
lipids, aiding their interaction with mitochondria [49]. Bcl-XL interferes
with this Bid-dependent process, and so reduces mitochondrial dam-
age initiated by oxidatively truncated phospholipids. Bid is therefore
a co-factor in the promotion of cellular death by truncated phospho-
lipids, while the actual effectors of apoptosis are oxidatively truncated
phospholipids.
Exogenous oxidatively truncated phospholipids are present and
increase over prolonged times in the circulation of apoE−/− animals
prone to atherosclerosis fed a western style diet [16]. Truncated phos-
pholipids are also a feature in the more rapidly induced oxidative and
inﬂammatory stress induced by chronic ethanol ingestion in both an
animal model [17] and humans [8,17,52]. The animal model of chronic
(but not excessive since the alcohol level approximates 0.1% v/v) ethanol
ingestion shows that truncated phospholipids accumulate in the circu-
lation just as the liver mounts an inﬂammatory response. The hystere-
sis in circulating oxidized and truncated phospholipids shows that
these do not correlate to the oxidative stress of ethanol catabolism,
but instead correlate to an inﬂammatory response that becomes signiﬁ-
cant after four weeks of ethanol ingestion. Ablation of the inﬂamma-
tory response by feeding the animals the small molecule taurine [53]
abolished accumulation of truncated phospholipid in the blood of
ethanol-fed animals [17]. Chronic inﬂammatory insults are therefore
a sufﬁcient stimulus to induce production and accumulation of oxida-
tively damaged phospholipids, which actually are only the visible portion
of a massive ﬂux of truncated phospholipids through the circulation, as
developed below.4.4. Endogenous truncated phospholipids
Phospholipid oxidation products accumulate in the external envi-
ronment of vascular cells and are internalized to initiate intrinsic
apoptosis, but these same oxidatively modiﬁed phospholipids are
also generated within cells either by photochemical oxidation or by
cellular metabolism. They are similarly cytotoxic.
Photochemical oxidation induces apoptosis and oxidatively trun-
cated phospholipids are formed when cells are irradiated with UVB
light [32]. Destruction of either the phospholipid hydroperoxide precur-
sors of truncated phospholipids formed during this oxidative stress
or their metabolism after oxidative fragmentation by over expressing
PAF acetylhydrolase abolishes UVB induced cell death [54]. Much of
the effect on the immune system and keratinocytes reﬂects the forma-
tion of PAF-like phospholipids [32] that stimulate the PAF receptor on
the external aspect of the cell, but also reﬂect internal truncated phos-
pholipids that act on PPARγ [37].
Oxidatively truncated phospholipids are directly formed within
cells through cellular metabolism. Cells responding to TNFα or Fas
Ligand stimulation activate their NADPH oxidase complex [67]. This
produces radicals, overwhelming cellular antioxidant defense, that
peroxidize cellular phospholipids. Either blockade of NADPH oxidase
activity or over-expression of the phospholipid speciﬁc glutathione
peroxidase 4 that chemically reduces phospholipid hydroperoxides
prevents accumulation of oxidatively truncated phospholipids. Both
maneuvers also prevent cytokine induced cell death. Conversely,
siRNA mediated loss of glutathione peroxidase 4 allows excessive per-
oxidized phospholipid formation, and it enhances cytokine cytotoxicity.
Phospholipid hydroperoxides are therefore essential components of
cytokine-stimulated apoptosis.
The question is whether phospholipid hydroperoxides are directly
cytotoxic, or whether their involvement stems from their oxidation
and fragmentation to truncated phospholipids. PAF acetylhydrolases
can resolve this difﬁcult problem because they speciﬁcally hydrolyze
oxidized phospholipids (below). Over-expression of type II PAF acetyl-
hydrolase reduces the cellular load of truncated phospholipids formed
in response to TNFα, and did so without reducing the increased cellular
content of phospholipid hydroperoxides. PAF acetylhydrolase expres-
sion fully protected cells from TNFα induced apoptosis, showing that
peroxidized phospholipids were only cytotoxic because they are pre-
cursors of truncated phospholipids that are the actual deleterious
agents.
These novel outcomes prove several issues. 1) PAF acetylhydrolase
substrates – likely the oxidatively truncated phospholipids that accu-
mulate after cytokine stimulation – are the key downstream compo-
nents of cytokine-induced apoptosis. 2) Oxidized phospholipids are
the actual mediators of Bid-enhanced apoptosis. Pro-apoptotic Bid
binds and transports lysolipids, so the way that Bid promotes apoptosis
is through increased accesses of truncated phospholipids to mitochon-
dria. That is, Bid is a co-factor that delivers the actual apoptoticmediator
to mitochondria 3) Accumulation of truncated phospholipids, whether
formed endogenously from cytokine or photochemical oxidation or
transported into the cell, increases the load of pro-apoptotic cellular
mediators. Cytokine signaling can be augmented through uptake and
mixing of exogenous truncated phospholipidswith internally generated
lipids. 4) The way reactive oxygen species are involved in cellular apo-
ptosis is not direct; they are required for the formation of truncated
phospholipids and it is oxidatively truncated phospholipids, rather
than reactive oxygen species themselves, that are directly apoptotic.
5) The primary determinants of resistance to oxidative stress are phos-
pholipid hydroperoxide reductive systems and/or intracellular hydro-
lytic enzymes that metabolize oxidized phospholipids and their
truncated products.
Overall, oxidation of cellular and circulating phospholipids forms
new structures with distinct and deﬁnable activities. Phospholipid
precursors are sequestered in membranes and lipoproteins, but
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soluble. Thesemobile structures no longer constrained to phospholip-
id bilayers, with motility aided by albumin in the circulation or Bid
within cells, display novel actions at external and internal receptors.
Several targets of these modiﬁed phospholipids have been deﬁned,
but new activities [5] await molecular identiﬁcation of their new tar-




Oxidative modiﬁcation of phospholipids primarily occurs at the
sn-2 glycerol carbon because that is the preferred site of polyunsatu-
rated phospholipid incorporation. Selective metabolism of oxidized
phospholipids also is targeted to this site. Phospholipases A2 act on
sn-2 residues, but the large number of enzymes and families [55] of
phospholipases A2 does not distinguish among the multitude of dif-
ferent sn-2 residues. Location of the ester bond in the glycerol back-
bone rather than the chemical identity of the fatty acyl substrate
constrains hydrolysis by this class of esterases. There are rare excep-
tions to this lack of identiﬁcation of substrates by phospholipases A2,
the arachidonoyl speciﬁc class IV phospholipase A2, and two families
(class VII and VIII) of PAF acetylhydrolases. The type I PAF acetylhydro-
lases of class VIII phospholipases A2 speciﬁcally hydrolyzes the acetyl
residue of PAF, and no other substrates. In contrast the class VII enzymes
hydrolyze PAF, but additionally contain an extended active site that
enables them to hydrolyze truncated and oxidized phospholipids [56].
The active site cannot accept intact, long chain phospholipids, and so
these enzymes are completely speciﬁc in attacking PAF and oxidized
phospholipids.
Protective hydrolysis of oxidatively damaged phospholipids is in
fact the likely original, and remaining, function of these unusual phos-
pholipases A2. Schizosaccharomyces pombe, a single celled yeast with
an estimated divergence time from us of 100 Ma, contains one of
the smallest genomes sequenced, yet it retains a PAF acetylhydrolase.
This Plg7 gene encodes a phospholipase A2 that is highly homologous
to mammalian group VII enzymes and hydrolyzes PAF, as expected,
but also effectively hydrolyzes truncated phospholipid [18]. This
yeast does not and cannot generate PAF. It does not possess any G
protein coupled receptors and so does not have a PAF receptor nor
does it respond to PAF, so the organism should not require a PAF acet-
ylhydrolase. Instead, the role of Plg7 is revealed when the cells are
loaded with polyunsaturated fatty acids and oxidized by a transition
metal. This oxidative stress is lethal, but over-expression of Plg7p
enzyme, or an intracellular mammalian group VII enzyme, protects
yeast against oxidative cell death. This outcome elucidates three
interconnected and critical points: oxidized phospholipids directly
cause oxidative death; depletion of oxidatively damaged phospho-
lipids by selective hydrolysis is protective during oxidant stress;
and, retention of a PAF acetylhydrolase over 100 Ma of evolution
shows that oxidized phospholipids remain a signiﬁcant threat.
PAF acetylhydrolase was originally puriﬁed from human plasma [57],
andnamedbased on its ability to hydrolyze the sn-2 acetyl residue of PAF.
A homologous intracellular enzyme, the type II PAF acetylhydrolase,
was puriﬁed from bovine liver and then cloned [58]. These enzymes,
along with that of S. pombe Plg7p, constitute the class VII phospholi-
pases A2. These enzymes hydrolyze PAF, but also are able to accommo-
date oxidatively damaged phospholipids in their active site. They do so
with complete speciﬁcity for oxidized phospholipids because they are
unable to attack biosynthetic phospholipids bearing long, unmodiﬁed
sn-2 fatty acyl residues [19]. A subsequent puriﬁcation of LDL-
associated phospholipase A2 from human plasma, where alignment
with the deposited human sequence identiﬁed it as plasma PAF acetyl-
hydrolase [59], conﬁrms PAF and oxidized phospholipids are theenzymes' sole substrates. These enzymes are Ca++-independent, and
so are present in a fully activated form with only substrate availability
regulating their action.
Two other phospholipases, Ca++-independent phospholipase A2
(iPLA2) and peroxiredoxin 6, also act on oxidized phospholipids, but
the role of both is complicated by their actions on normal phospho-
lipids. Peroxiredoxin 6 is a protective antioxidant that both chemically
reduces water-soluble and phospholipid hydroperoxides, and hydro-
lyzes phospholipids prior to their oxidative fragmentation through a
second active site [60,61].
5.2. Transport and clearance
Plasma PAF acetylhydrolase is the sole enzyme in the circulation
that hydrolyzes and inactivates PAF [56], and accordingly would be
expected to be the sole mechanism to control the level of circulating
PAF and truncated phospholipid substrates. These events, however, are
unrelated. The primaryway these phospholipids are cleared from blood
is through their uptake into liver and kidney [62]. Uptake is so rapid,
with a half life less than 30 s, that not only is it difﬁcult to accurately
measure, it is far faster than circulating plasma PAF acetylhydrolase
can metabolize PAF. In vivo studies also show that PAF and a truncated
phospholipid compete for uptake, suggesting a commonmechanism for
clearance [62]. Circulating PAF acetylhydrolase instead may be more
important to themetabolismof peroxidized [63] and oxidized phospho-
lipids [64] associated with the low density lipoproteins that bind and
transport plasma PAF acetylhydrolase than to water soluble PAF and
truncated phospholipids.
Uptake of phospholipids into cells, let alone tissues, occurs through a
largely unknown entity(ies), but clearly is distinct from the opposite
one way efﬂux processes that enhance ﬂow of bulk phospholipid,
cholesterol and phosphatidylserine from the intracellular to the extra-
cellular compartment. In contrast to mammalian cells, phospholipid
uptake is genetically deﬁned in the yeast Saccharomyces cerevisiae. In
these single cells, uptake of PAF and short-chained phospholipids de-
pends on a two-component system of a P4-type ATPase transporter
and a second subunit, independently identiﬁed as Ros3 and Lem3 [65].
Mammalian cells expressmRNA that encodes a related gene, and expres-
sion of this TMEM30a partially rescues yeast with genetically deleted
Ros3 [11]. Conversely, knockdown of TMEM30a reduces PAF and trun-
cated phospholipid uptake in mammalian cells. From this, we conclude
that mammalian cells accumulate exogenous phospholipids that are suf-
ﬁciently water soluble to be presented asmonomericmolecules through
a transport system(s) that includes TMEM30a. TMEM30a is present in
endothelial cells, but we do not yet know whether it participates in the
rapid clearance of oxidized phospholipids from the circulation. Oxidized
phospholipids can therefore be internalized independently of intact oxi-
dized lipoprotein particles.
6. Summary
Chemical or enzymatic oxidation of phospholipid with sn-2 polyun-
saturated fatty acyl residues generates phospholipid (hydro)peroxides,
with preferential oxidation of outer oleﬁnic bonds in polyunsaturated
fatty acyl residues. These oxidativelymodiﬁed phospholipids are friable
and subject to chemical decomposition by β-scission at the site of the
peroxy function. The fragments from the ω-end of the esteriﬁed fatty
acyl residue are water-soluble, but the truncated fatty acyl fragments
arising from the proximal α-end of the fatty acyl residue remain ester-
iﬁed in the phospholipid. These truncated phospholipids range in
length, depending on the location of the original double bond in the
polyunsaturated fatty acyl reside, and in their solubility and disruption
of phospholipid packing. These esteriﬁed fragments may or may not
terminate with the newly introduced oxygen molecule, and this de-
pends on which side of the peroxy function cleavage occurred. Deﬁned
2463T.M. McIntyre / Biochimica et Biophysica Acta 1818 (2012) 2456–2464oxidized phospholipids also have been shown to be the ligands for and
agonists of CD36, reviewed separately [7].
Truncated phospholipid with short sn-2 fragments activates the
innate immune system at multiple points through their mimicry of
the potent inﬂammatory mediator PAF. Phospholipids bearing inter-
mediate length fragments are agonists of the lipid-activated transcrip-
tion factor PPARγ. Truncated phospholipids with the longer 9-carbon
sn-2 fragment derived from linoleoyl and linolenoyl fragmentation
interact with mitochondria in a Bid-aided way to induce the caspase cas-
cade of intrinsic apoptosis. Oxidatively truncated phospholipids are selec-
tively internalized in part by a transport system employing TMEM30a,
but also are formed within cells responding to cytokine stimulation.
Oxidized phospholipids are speciﬁcally hydrolyzed by dedicated phos-
pholipases A2, and these PAF acetylhydrolases have been conserved
since ancient times to protect cells from oxidative cell death.Acknowledgements
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